MedPath

A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS

Phase 2
Conditions
Acute Ischemic Stroke
Interventions
Drug: LT3001 Drug Product
Drug: Placebo
Registration Number
NCT04091945
Lead Sponsor
Lumosa Therapeutics Co., Ltd.
Brief Summary

This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
24
Inclusion Criteria
  • 18 to 90 years
  • NIHSS of 4 to 30
  • Diagnosis of AIS within 24 hours after stroke symptoms onset
Exclusion Criteria
  • Treatement with approved drug during the current AIS
  • Pre-stroke disability
  • Imaging evidence of acute intracranial hemorrhage, intraparenchymal tumor, arteriovenous malformations, other central nervous system lesions that could increase bleeding risk, or aneurysm requiring treatment
  • Suspected subarachnoid hemorrhage
  • Seizure
  • Uncontrolled hypertension
  • INR >1.7 and/or abnormal aPTT or platelet count <100,000/mm3
  • Blood glucose concentration <50 mg/dL or >400 mg/dL
  • Lactating or pregnant subjects or those planning to become pregnant during the study
  • Received anticoagulants and/or antiplatelet therapy and glycoprotein IIb/IIIa inhibitors within 48 hours
  • AIS, myocardial infarction, serious head trauma or major surgery within 90 days
  • Bleeding event within 21 days
  • Puncture of noncompressible vessels within 7 days
  • Severe hepatic, renal, and/or infectious disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LT3001 Drug ProductLT3001 Drug Product-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
The percentage of subject have symptomatic intracranial hemorrhage (sICH) of a single dose LT3001 drug product in subjects with AIS.Within 36 hours

Compare the the percentage of subject having symptomatic intracranial hemorrhage (sICH) between LT3001 drug product and Placebo.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (10)

China Medical University Hospital

πŸ‡¨πŸ‡³

Taichung, Taiwan

Chattanooga Center for Neurologic Research

πŸ‡ΊπŸ‡Έ

Chattanooga, Tennessee, United States

JFK Neuroscience Institute, JFK Medical Center

πŸ‡ΊπŸ‡Έ

Edison, New Jersey, United States

University of Kentucky Chandler Medical Center

πŸ‡ΊπŸ‡Έ

Lexington, Kentucky, United States

Kaohsiung Medical University Chung-Ho Memorial Hospital

πŸ‡¨πŸ‡³

Kaohsiung, Taiwan

Linkou Chang Gung Memorial Hospital

πŸ‡¨πŸ‡³

New Taipei City, Taiwan

Taichung Veterans General Hospital

πŸ‡¨πŸ‡³

Taichung, Taiwan

Taipei Medical University - Shuang Ho Hospital

πŸ‡¨πŸ‡³

New Taipei City, Taiwan

Taipei Veterans General Hospital

πŸ‡¨πŸ‡³

Taipei, Taiwan

The Ohio State University - Wexner Medical Center

πŸ‡ΊπŸ‡Έ

Columbus, Ohio, United States

Β© Copyright 2025. All Rights Reserved by MedPath